, /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will be participating at the upcoming conferences: taking place in and at the taking place in . This year at the EHA 2024 Congress, , MD, Ph.D.
, Chief Medical Officer of Halia will be presenting a poster, entitled "Trial In Progress: Phase II Study of the NLRP3 Inflammasome & Myddosome Inhibitor HT-6184 in Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS)". Dr. Amsbury will highlight preliminary data from the ongoing Phase IIa study evaluating the efficacy, safety, and pharmacodynamics of HT-6184 administered in patients with varying diagnosis of MDS.
"We are thrilled to share preliminary results from our Phase II study evaluating our lead asset HT-6184 in MDS patients" said Dr. Amsbury, Chief Medical Officer of Halia Therapeutics. "Initial data are encouraging, and we are confident that we will be able to advance development of HT-6184, bringing a much-needed therapeutic option for those affected by this challenging condition.
Our team remains dedicated to advancing this research and exploring the full potential of HT-6184 mediated NLRP3-inhibition for improving patient outcomes across many different therapeutic areas". , Ph.D.
, President and CEO, , MBA Chief Operating Officer and , MD, Ph.D., Chief Medical Officer, will be available for meetings at BIO 202.
